hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06329882, orgStudyIdInfo id: 14789, briefTitle: Doxycycline in Type II Diabetes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2025-03-20, completionDateStruct date: 2025-04-20, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Mostafa Bahaa, class: OTHER, descriptionModule briefSummary: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden, conditionsModule conditions: Diabetes Mellitus, Type 2, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: open label, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: open label, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Sitagliptin 100mg, interventions name: Doxycyclin, outcomesModule primaryOutcomes measure: Change in glycemic profile, primaryOutcomes measure: Change in glycemic profile, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 60 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06329869, orgStudyIdInfo id: 202401158MIFD, briefTitle: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma, acronym: SG-ESCC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2027-11, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: National Taiwan University Hospital, class: OTHER, collaborators name: Gilead Sciences, descriptionModule briefSummary: The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma., conditionsModule conditions: Esophageal Squamous Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Sacituzumab govitecan, outcomesModule primaryOutcomes measure: Overall objective response rates (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], otherOutcomes measure: Biomarkers-related endpoints, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06329843, orgStudyIdInfo id: Intermountain, briefTitle: Intermountain Inpatient Bilirubin Decision Accuracy Study Using Smartphone-based Measurements by Picterus Jaundice Pro, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Picterus AS, class: INDUSTRY, collaborators name: Intermountain Medical Center, descriptionModule briefSummary: The goal of this project is to evaluate the performance of Picterus Jaundice Pro in an American population, including preterm and term newborns and pre- and post- phototherapy., conditionsModule conditions: Neonatal Jaundice, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Picterus Jaundice Pro (JP), outcomesModule primaryOutcomes measure: Enable high qualitative estimation of bilirubin levels in the blood of term and preterm newborns undergoing phototherapy using Picterus JP., secondaryOutcomes measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from term-born babies without phototherapy., secondaryOutcomes measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from preterm-born babies without phototherapy., secondaryOutcomes measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from term-born babies who have received phototherapy., secondaryOutcomes measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from preterm-born babies who have received phototherapy., eligibilityModule sex: ALL, minimumAge: 12 Hours, maximumAge: 192 Hours, stdAges: CHILD, contactsLocationsModule locations facility: Intermountain Health, status: RECRUITING, city: Salt Lake City, state: Utah, zip: 84132, country: United States, contacts name: Timothy M Bahr, MS MD, role: CONTACT, phone: 801-602-6523, email: Tim.Bahr@imail.org, contacts name: Kimberlee W Lewis, MS RN, role: CONTACT, phone: 801.507.7675, email: [kimberlee.weaverlewis@imail.org, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06329830, orgStudyIdInfo id: 2023-GAR-001, briefTitle: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer, acronym: LUNAAR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2028-05, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Rohan Garje, class: OTHER, collaborators name: Janssen Scientific Affairs, LLC, descriptionModule briefSummary: The purpose of this research study is to test the safety and possible side effects of Lutetium-177 (177Lu)-Prostate-Specific Membrane Antigen (PSMA)-617 along with niraparib and abiraterone acetate plus prednisone when it is given to people diagnosed with metastatic castration-resistant prostate cancer (prostate cancer that has spread to other parts of the body and does not improve with hormonal therapies) at different dose levels. Once an optimal dose is selected, the researchers want to find out what how well these treatments work to improve survival and control the growth of the tumor., conditionsModule conditions: Metastatic Prostate Cancer, conditions: Castration-resistant Prostate Cancer, conditions: Metastatic Castration-resistant Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: 177Lu-PSMA-617, interventions name: Niraparib abiraterone acetate, interventions name: Prednisone, outcomesModule primaryOutcomes measure: Determination of the recommended phase 2 dose (RP2D), primaryOutcomes measure: Prostatic-specific antigen (PSA)-50 response rate, secondaryOutcomes measure: Radiographic progression-free survival (rPFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: PSA-80 response rate, secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Objective response rate (ORR), eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Miami Cancer Institute, city: Miami, state: Florida, zip: 33176, country: United States, contacts name: Rohan Garje, M.D., role: CONTACT, phone: 786-596-2000, email: rohan.garje@baptisthealth.net, contacts name: Leslie Castaneda, role: CONTACT, phone: (786) 596-2000, email: leslie.castaneda@baptisthealth.net, geoPoint lat: 25.77427, lon: -80.19366, hasResults: False
protocolSection identificationModule nctId: NCT06329817, orgStudyIdInfo id: A/28/ER/532/23, briefTitle: Incidence of Regurgitation in Patients Undergoing Intubation in Semi-fowler v/s Supine Position, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Pak Emirates Military Hospital, class: OTHER, descriptionModule briefSummary: One of the most dreaded complication of general anaesthesia is aspiration of gastric contents after induction of general anaesthesia.Many endeavours and measures have been practiced to reduce the incidence of aspiration pneumonia.One such method is to intubate the patient in semi-fowler or supine posture.My study is aimed to find out safe and best position between these two after induction of general anaesthesia to prevent aspiration pneumonia., conditionsModule conditions: Inguinal Hernia Bilateral, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Incidence of regurgitation in two different position., outcomesModule primaryOutcomes measure: Prevention of aspiration pneumonia, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: PEMH, status: RECRUITING, city: Rawalpindi, state: Punjab, zip: 44000, country: Pakistan, contacts name: PEMH, role: CONTACT, phone: +923317055191, email: rabbiafatimasattar555@gmail.com, geoPoint lat: 33.6007, lon: 73.0679, hasResults: False
protocolSection identificationModule nctId: NCT06329778, orgStudyIdInfo id: 50884b, briefTitle: Home-Based Child Care Toolkit for Nurturing School-Age Children Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-10-27, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Mathematica Policy Research, Inc., class: OTHER, collaborators name: Department of Health and Human Services, descriptionModule briefSummary: The goal of this observational study is to build psychometric evidence for the Home-Based Child Care Toolkit for Nurturing School-Age Children (HBCC-NSAC Toolkit) provider questionnaire. The main objectives of the study are to: 1) assess the reliability of the HBCC-NSAC Toolkit provider questionnaire, 2) assess the evidence for its validity compared to other existing measures of HBCC quality, and 3) examine invariance across subgroups (that is, look for the absence of any differential item functioning \[DIF\]). HBCC provider participants will complete a questionnaire in the HBCC-NSAC Toolkit. A subset of providers will also participate in an observation of their child care setting. Parents or guardians of children receiving care from HBCC providers will complete a survey., conditionsModule conditions: Child Development, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 316, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: The Home-Based Child Care Toolkit for Nurturing School-Age Children provider questionnaire, primaryOutcomes measure: Emlen Scales, primaryOutcomes measure: Multicultural Teaching Competency Scale, primaryOutcomes measure: Family Child Care Program Quality Assessment (FCC PQA), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mathematica Policy Research, status: RECRUITING, city: Washington, state: District of Columbia, zip: 20002, country: United States, contacts name: Ashley Kopack Klein, role: CONTACT, phone: 202-484-9220, email: lakopackklein@mathematica-mpr.com, geoPoint lat: 38.89511, lon: -77.03637, hasResults: False
protocolSection identificationModule nctId: NCT06329752, orgStudyIdInfo id: Not available yet, briefTitle: Sciatic Nerve Block for Ankle and Leg Fracture Manipulation in the Emergency Department, acronym: AnkleMan, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: IRCCS Policlinico S. Matteo, class: OTHER, descriptionModule briefSummary: The goal of this feasibility clinical trial is to assess the acceptability of ultrasound-guided sciatic nerve block when performed at Emergency Departments for manipulation and temporary stabilization of distal leg and ankle fractures.The trial aims to assess:* The acceptability of sciatic nerve block* The technical feasibility of sciatic nerve block* The technical success of sciatic nerve block* The analgesic efficacy of sciatic nerve blockIn addition to that, this study aims to* Describe patient-reported and physician-reported satisfaction* Assess the Adverse Event rate at 48 hours post intervention, conditionsModule conditions: Ankle Fractures, conditions: Leg Fracture, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Interventional, single-arm, feasibility trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine), outcomesModule primaryOutcomes measure: To assess the technical feasibility of ultrasound-guided sciatic nerve block when performed at Emergency Departments for manipulation and temporary stabilization of distal leg and ankle fractures., secondaryOutcomes measure: Technical success of US-guided sciatic nerve block, secondaryOutcomes measure: Analgesic efficacy of US-guided sciatic nerve block, secondaryOutcomes measure: Patient-reported and physician-reported satisfaction, otherOutcomes measure: Safety Endpoint, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Emergency Department, IRCCS Fondazione Policlinico San Matteo, city: Pavia, zip: 27100, country: Italy, contacts name: Santi Di Pietro, role: CONTACT, phone: 3463153244, email: santi.dipietro@unipv.it, geoPoint lat: 45.19205, lon: 9.15917, hasResults: False
protocolSection identificationModule nctId: NCT06329739, orgStudyIdInfo id: NeuroPsico_Dopa&PD, briefTitle: Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-12-14, primaryCompletionDateStruct date: 2031-12-14, completionDateStruct date: 2031-12-14, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, class: OTHER, descriptionModule briefSummary: The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a significant minority in PD cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic PD. This knowledge has the potential to have a major impact in the clinical care of people with PD.The goal of this observational study is to evaluate the impact of genetic mutation on behavior and cognition in PD patients.Patients will be assessed over time using test, questionnaire and standardised clinica scales. An initial assessment and annual follow-up assessments will be carried out for 5 years.Researchers will compare data collected from patients with genetic mutation versus patients without mutation., conditionsModule conditions: Parkinson Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: Clinical examinations and clinical scales administration, outcomesModule primaryOutcomes measure: Montreal Cognitive Assessment, primaryOutcomes measure: Beck Depression Inventory, primaryOutcomes measure: State-Trait Anxiety Inventory, primaryOutcomes measure: Questionnaire for Impulsive-Compulsive Disorders in Parkinson, primaryOutcomes measure: Pittsburgh Sleep Quality Index, primaryOutcomes measure: Parkinson's Disease Questionnaire-8, primaryOutcomes measure: Minnesota Multiphasic Personality Inventory 2-RF, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, status: RECRUITING, city: Milan, zip: 20122, country: Italy, contacts name: Francesca Mameli, role: CONTACT, phone: 0255033621, email: francesca.mameli@policlinico.mi.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06329726, orgStudyIdInfo id: NeuroPsico_DBS&PD, briefTitle: Long-Term Behavioral and Cognitive Outcomes of Deep Brain Stimulation in Patients With Parkinson's Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-12-13, primaryCompletionDateStruct date: 2031-12-15, completionDateStruct date: 2032-12-15, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to evaluate the long-term effect of DBS-STN on cognitive and behavioral outcomes in Parkinson's disease (PD) patients.PD patients will be assessed over time using tests, questionnaires and standardized clinical scales. An initial assessment (T0) and annual follow-up assessments will be carried out for 5 years.Researchers will compare data collected from patients with DBS versus patients with best medical therapy., conditionsModule conditions: Parkinson Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: Clinical examinations and clinical scales administration, outcomesModule primaryOutcomes measure: Long-term characterization of DBS-STN on cognitive outcomes, primaryOutcomes measure: Beck Depression Inventory, primaryOutcomes measure: State-Trait Anxiety Inventory, primaryOutcomes measure: Questionnaire for Impulsive-Compulsive Disorders in Parkinson, primaryOutcomes measure: Pittsburgh Sleep Quality Index, primaryOutcomes measure: Parkinson's Disease Questionnaire-8, primaryOutcomes measure: Minnesota Multiphasic Personality Inventory 2-RF, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, status: RECRUITING, city: Milan, state: Lombardia, zip: 20135, country: Italy, contacts name: Eleonora Zirone, Dr, role: CONTACT, phone: 0255038671, phoneExt: 0039, email: eleonora.zirone@policlinico.mi.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06329713, orgStudyIdInfo id: 2024-03/11, briefTitle: Effect of Auto-Bolus Interval on Analgesic Quality During Labor Analgesia With Dural Puncture Epidural, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Ataturk University, class: OTHER, descriptionModule briefSummary: It is aimed in this study to compare the effect of changing the interval time for programmed auto boluses of local anaesthetics on the total anesthetic consumption and quality of labor analgesia with dural puncture epidural technique., conditionsModule conditions: Analgesia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Group I: 30 Min Interval Time, interventions name: Group II: 60 Min Interval Time, outcomesModule primaryOutcomes measure: Difference between total local anaesthetic consumption, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Atatürk University, status: RECRUITING, city: Erzurum, country: Turkey, contacts name: Ayşenur Dostbil, role: CONTACT, phone: +905333677796, email: adostbil@hotmail.com, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06329700, orgStudyIdInfo id: ParSparInLivAtrophy, briefTitle: Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy, statusModule overallStatus: COMPLETED, startDateStruct date: 2010-05-01, primaryCompletionDateStruct date: 2019-12-31, completionDateStruct date: 2022-06-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Azienda Ospedaliero Universitaria Maggiore della Carita, class: OTHER, descriptionModule briefSummary: Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. The aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing PSH for CLM. For this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality., conditionsModule conditions: Colorectal Cancer Stage IV, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 74, type: ACTUAL, armsInterventionsModule interventions name: Hepatectomy, outcomesModule primaryOutcomes measure: Postoperative complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False